These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15310724)

  • 1. Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies.
    Lown JA; Hughes AS; Cannell P
    Heart; 2004 Sep; 90(9):e55. PubMed ID: 15310724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
    Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
    Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy.
    Jubelirer SJ; Koenig BA; Bates MC
    Am J Hematol; 1999 Jul; 61(3):205-8. PubMed ID: 10398314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
    Joseph T; Marco J; Gregorini L
    Clin Cardiol; 1998 Nov; 21(11):851-2. PubMed ID: 9825202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed immunologic thrombocytopenia induced by abciximab.
    Nurden P; Clofent-Sanchez G; Jais C; Bermejo E; Leroux L; Coste P; Nurden AT
    Thromb Haemost; 2004 Oct; 92(4):820-8. PubMed ID: 15467914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
    Rasti M; Blostein M
    Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.
    Curtis BR; Swyers J; Divgi A; McFarland JG; Aster RH
    Blood; 2002 Mar; 99(6):2054-9. PubMed ID: 11877279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion.
    Kereiakes DJ; Essell JH; Abbottsmith CW; Broderick TM; Runyon JP
    Am J Cardiol; 1996 Nov; 78(10):1161-3. PubMed ID: 8914883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration.
    Webb GJ; Swinburn JM; Grech H
    Platelets; 2011; 22(4):302-4. PubMed ID: 21526887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
    Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
    Butler R; Hubner PJ
    Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profound thrombocytopenia caused by abciximab infusion following.
    Daley B; Miranda D; Kalra A; Pease D
    Minn Med; 2014 Oct; 97(10):48-9. PubMed ID: 25651641
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.
    Rao J; Mascarenhas DA
    J Invasive Cardiol; 2001 Jun; 13(6):471-3. PubMed ID: 11385174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.
    Golden T; Ghazala S; Wadeea R; Junna S
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F; Oza R; Mascarenhas DA
    J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.